Residency · Residency · General Surgery
Soft Tissue Sarcoma: Diagnosis and Surgical Management
Introduction
Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies that account for approximately 1% of all adult cancers. With over 50 histologic subtypes recognized by the WHO classification, these tumors arise from connective tissues including muscle, fat, fibrous tissue, blood vessels, and peripheral nerves. The general surgeon must be adept at recognizing these lesions, performing appropriate workup, and executing oncologically sound resections.
Epidemiology and Risk Factors
Approximately 13,000 new cases are diagnosed per year in the United States. Soft tissue sarcomas can occur at any age, with peak incidence in the 5th and 6th decades. Prior radiation therapy is a recognized risk factor, with radiation-associated sarcomas typically arising 5-10 years after treatment, most commonly as undifferentiated pleomorphic sarcoma or angiosarcoma. Genetic syndromes associated with STS include Li-Fraumeni syndrome (TP53 mutations), neurofibromatosis type 1 (which carries a risk of malignant peripheral nerve sheath tumor), familial adenomatous polyposis (associated with desmoid tumors), and retinoblastoma (RB1 mutations). Chronic lymphedema predisposes to Stewart-Treves syndrome (lymphangiosarcoma). Chemical exposures including vinyl chloride (associated with hepatic angiosarcoma), herbicides, and dioxin have also been implicated.
Clinical Presentation and Evaluation
Most soft tissue sarcomas present as a painless, enlarging mass in the extremity (60%), retroperitoneum (15-20%), or trunk and head and neck. Physical examination should assess size, depth relative to fascia, mobility, and relationship to neurovascular structures. Any soft tissue mass that is greater than 5 cm, deep to fascia, or rapidly growing should be considered malignant until proven otherwise. MRI with gadolinium is the gold standard imaging modality for extremity and trunk lesions, providing superior soft tissue contrast. CT with intravenous contrast is preferred for retroperitoneal and visceral sarcomas. Chest CT is obtained for staging, as the lungs are the most common site of distant metastasis for extremity STS. PET/CT may be useful for grading and detecting occult metastases but is not routinely recommended.
<image>MRI of an extremity soft tissue sarcoma showing a large heterogeneous mass deep to the muscular fascia with areas of necrosis and contrast enhancement, with labeled anatomical landmarks</image>
Biopsy Techniques
Core needle biopsy is the preferred initial technique because it provides tissue architecture for histologic subtyping and grading. Incisional biopsy may be necessary when core biopsy is non-diagnostic and must be planned along the axis of the limb in line with the definitive resection incision. Excisional biopsy is only appropriate for superficial lesions smaller than 3 cm where wide margins can be achieved. Fine needle aspiration alone is insufficient for initial diagnosis but may be useful for confirming recurrence. The critical principle is that biopsy tracts must be excised en bloc with the definitive resection specimen, as poorly planned biopsies can compromise limb-sparing surgery.
Staging and Grading
| FNCLCC Grade | Score | Differentiation | Mitotic Count | Necrosis | Metastatic Risk |
|---|---|---|---|---|---|
| Grade 1 (Low) | 2–3 | Well differentiated | 0–9/10 HPF | None | <15% |
| Grade 2 (Intermediate) | 4–5 | — | 10–19/10 HPF | <50% | ~30% |
| Grade 3 (High) | 6–8 | Poorly differentiated | ≥20/10 HPF | ≥50% | >40% |
The AJCC 8th edition staging system incorporates tumor size, grade, and depth. The FNCLCC grading system (French Federation of Cancer Centers) is the most widely used and is based on tumor differentiation, mitotic count, and tumor necrosis, assigning tumors as Grade 1 (low), Grade 2 (intermediate), or Grade 3 (high). Grade is the single most important prognostic factor for distant metastasis and overall survival. Retroperitoneal sarcomas have a separate AJCC staging system as of the 8th edition.
Histologic Subtypes of Clinical Importance
Undifferentiated pleomorphic sarcoma (UPS) is the most common STS in adults and demonstrates high-grade, aggressive behavior. Liposarcoma includes well-differentiated (atypical lipomatous tumor), dedifferentiated, myxoid/round cell, and pleomorphic subtypes with vastly different prognoses. Leiomyosarcoma arises from smooth muscle and is common in the retroperitoneum and uterus. Synovial sarcoma is characterized by a distinct t(X;18) translocation, often affects young adults, and is chemosensitive. Gastrointestinal stromal tumor (GIST) harbors KIT or PDGFRA mutations, is treated with imatinib, and follows a separate management paradigm. Desmoid tumors (aggressive fibromatosis) are locally aggressive but do not metastasize, and observation is increasingly the first-line approach.
<image>Histopathology comparison of four major soft tissue sarcoma subtypes showing undifferentiated pleomorphic sarcoma, well-differentiated liposarcoma, leiomyosarcoma, and synovial sarcoma with characteristic morphologic features labeled</image>
Surgical Management Principles
Wide local excision with negative margins (R0) is the cornerstone of curative treatment. A margin of 1-2 cm or an intact fascial plane is generally accepted as adequate. Limb-sparing surgery is possible in more than 90% of extremity STS when combined with radiation therapy. Amputation is reserved for cases where a functional limb cannot be preserved or when neurovascular involvement precludes limb-sparing resection. Re-excision is indicated after unplanned excision (the "whoops" procedure), as residual tumor is found in up to 30-50% of re-excision specimens. Retroperitoneal sarcomas often require multivisceral resection, and contiguous organ resection should be planned preoperatively based on imaging.
Adjuvant and Neoadjuvant Therapy
Neoadjuvant radiation (50 Gy) uses a smaller field but has a higher wound complication rate (35% versus 17%) and is preferred for large and deep tumors. Adjuvant radiation (60-66 Gy) uses a larger field with lower acute wound complications but higher late fibrosis and edema. Radiation is indicated for high-grade tumors, tumors greater than 5 cm, deep tumors, or those with close or positive margins. Doxorubicin-based regimens are the most active chemotherapy agents for STS. Neoadjuvant chemotherapy may be considered for large, high-grade extremity STS, though its role in retroperitoneal sarcoma remains controversial. Histotype-tailored therapy includes ifosfamide for synovial sarcoma, trabectedin for myxoid liposarcoma, and pazopanib for non-adipocytic STS.
Surveillance and Recurrence
Local recurrence rates are 10-20% with appropriate surgery and radiation. Distant metastasis occurs in 25-50% of high-grade tumors, predominantly to the lungs. The surveillance schedule includes physical exam and chest imaging every 3-6 months for 2-3 years, then every 6-12 months to year 5, and then annually. Pulmonary metastasectomy may be considered in select patients with isolated, resectable lung metastases and favorable tumor biology.
<image>Surgical planning diagram for wide local excision of an extremity soft tissue sarcoma showing the planned margins, biopsy tract inclusion, and relationship to major neurovascular bundle with annotation of the fascial envelope</image>
Key Clinical Pearls
Soft tissue masses that are greater than 5 cm, deep to fascia, or enlarging should always be biopsied before definitive excision. The biopsy tract must be planned along the longitudinal axis of the extremity so it can be excised with the definitive specimen. Grade is the most important prognostic factor and drives decisions about adjuvant therapy and surveillance intensity. Patients should be referred to a sarcoma center whenever possible, as multidisciplinary management improves outcomes. Unplanned excisions ("whoops" procedures) are common and necessitate re-excision at a specialized center.
References
- Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416-422.
- NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2024. National Comprehensive Cancer Network.
- O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235-2241.
- Gronchi A, Strauss DC, Miceli R, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (TARPSWG): a multicentre analysis. Lancet Oncol. 2016;17(4):477-488.
